Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

Regeneron is humming along on the strength Eylea and Dupixent. Now, it’s expanding its production to keep up with that growth.

Dr. Reddy’s, which has been dealing with manufacturing setbacks, has received a complete response letter for two potentially lucrative products. 

Novartis says it launched a probe of Zolgensma data manipulation in March but FDA records show some lab data was not reviewed until May.

The way CEO Kåre Schultz figures it, Teva Pharmaceutical can make more manufacturing cuts after reaching its $3 billion cost reduction goal.